👏 Congratulations to the #ESMOMeritAward recipients at #ESMOGI26.
These young researchers are recognised for the scientific merit of their abstracts.
🔗 https://ow.ly/rNGg50ZjbTo
#GICancers #GIOncology
These young researchers are recognised for the scientific merit of their abstracts.
🔗 https://ow.ly/rNGg50ZjbTo
#GICancers #GIOncology
July 1, 2026 at 1:45 PM
👏 Congratulations to the #ESMOMeritAward recipients at #ESMOGI26.
These young researchers are recognised for the scientific merit of their abstracts.
🔗 https://ow.ly/rNGg50ZjbTo
#GICancers #GIOncology
These young researchers are recognised for the scientific merit of their abstracts.
🔗 https://ow.ly/rNGg50ZjbTo
#GICancers #GIOncology
📍We are in Munich for #ESMOGI26. Come and visit us at our booth #34 on the first floor.
Don’t miss the Rapid Oral Session at 09:35 on Saturday where Angelica Petrillo will be presenting the #ASPIRE study results.
@myesmo.bsky.social
#ClinicalTrials #CancerResearch #Oncology
Don’t miss the Rapid Oral Session at 09:35 on Saturday where Angelica Petrillo will be presenting the #ASPIRE study results.
@myesmo.bsky.social
#ClinicalTrials #CancerResearch #Oncology
July 1, 2026 at 1:11 PM
📍We are in Munich for #ESMOGI26. Come and visit us at our booth #34 on the first floor.
Don’t miss the Rapid Oral Session at 09:35 on Saturday where Angelica Petrillo will be presenting the #ASPIRE study results.
@myesmo.bsky.social
#ClinicalTrials #CancerResearch #Oncology
Don’t miss the Rapid Oral Session at 09:35 on Saturday where Angelica Petrillo will be presenting the #ASPIRE study results.
@myesmo.bsky.social
#ClinicalTrials #CancerResearch #Oncology
Clinical trials can take years to build…but sometimes can disappear in a single day…
➡️ How can we better protect the social contract of clinical trials research?
#BATTMAN #trust #accountability #trialsresearch #cancer
www.linkedin.com/posts/sharle...
➡️ How can we better protect the social contract of clinical trials research?
#BATTMAN #trust #accountability #trialsresearch #cancer
www.linkedin.com/posts/sharle...
#colorectalcancer #immunotherapy #mcrc #esmogi26 | Sharlene Gill MD, MPH, MBA, FASCO
Earlier this week, the biotechnology company Agenus unexpectedly announced that it was discontinuing support for the Phase III BATTMAN (CCTG CO.33) clinical trial, abruptly ending an ambitious interna...
www.linkedin.com
July 18, 2026 at 8:02 PM
Clinical trials can take years to build…but sometimes can disappear in a single day…
➡️ How can we better protect the social contract of clinical trials research?
#BATTMAN #trust #accountability #trialsresearch #cancer
www.linkedin.com/posts/sharle...
➡️ How can we better protect the social contract of clinical trials research?
#BATTMAN #trust #accountability #trialsresearch #cancer
www.linkedin.com/posts/sharle...
📣 Register now for ESMO GI 2026
⏰Early registration ends tomorrow—secure the best available fees. Join experts to connect, share insights, and shape the future of GI cancers care. Munich & online, 1–4 July.
🔗 buff.ly/zWGXxWx
#ESMOGI26 #esmomeetings
⏰Early registration ends tomorrow—secure the best available fees. Join experts to connect, share insights, and shape the future of GI cancers care. Munich & online, 1–4 July.
🔗 buff.ly/zWGXxWx
#ESMOGI26 #esmomeetings
April 14, 2026 at 7:03 AM
📣 Register now for ESMO GI 2026
⏰Early registration ends tomorrow—secure the best available fees. Join experts to connect, share insights, and shape the future of GI cancers care. Munich & online, 1–4 July.
🔗 buff.ly/zWGXxWx
#ESMOGI26 #esmomeetings
⏰Early registration ends tomorrow—secure the best available fees. Join experts to connect, share insights, and shape the future of GI cancers care. Munich & online, 1–4 July.
🔗 buff.ly/zWGXxWx
#ESMOGI26 #esmomeetings
📣 Register now! Join ESMO GI 2026, the global meeting point where collaboration thrives and science moves into practice in GI oncology. See you in Munich, Germany, 📅 from 1 to 4 July 2026. #ESMOGI26 #esmomeetings
🔗 buff.ly/yRXZQxI
🔗 buff.ly/yRXZQxI
January 23, 2026 at 8:31 AM
📣 Register now! Join ESMO GI 2026, the global meeting point where collaboration thrives and science moves into practice in GI oncology. See you in Munich, Germany, 📅 from 1 to 4 July 2026. #ESMOGI26 #esmomeetings
🔗 buff.ly/yRXZQxI
🔗 buff.ly/yRXZQxI
👉 From data to impact.
Discover how your abstract can help shape progress in GI cancer care at ESMO GI 2026, Munich, 1–4 July 2026.
#ESMOGI26 #esmomeetings
SUBMIT YOUR ABSTRACT NOW!
🔗 https://ow.ly/HQLX50Y8NgY
Discover how your abstract can help shape progress in GI cancer care at ESMO GI 2026, Munich, 1–4 July 2026.
#ESMOGI26 #esmomeetings
SUBMIT YOUR ABSTRACT NOW!
🔗 https://ow.ly/HQLX50Y8NgY
February 5, 2026 at 3:02 PM
👉 From data to impact.
Discover how your abstract can help shape progress in GI cancer care at ESMO GI 2026, Munich, 1–4 July 2026.
#ESMOGI26 #esmomeetings
SUBMIT YOUR ABSTRACT NOW!
🔗 https://ow.ly/HQLX50Y8NgY
Discover how your abstract can help shape progress in GI cancer care at ESMO GI 2026, Munich, 1–4 July 2026.
#ESMOGI26 #esmomeetings
SUBMIT YOUR ABSTRACT NOW!
🔗 https://ow.ly/HQLX50Y8NgY
📣 The future of GI oncology is written together. Registration is now open for the ESMO Gastrointestinal Cancers Congress 2026, taking place in Munich, Germany, 1–4 July. A global stage for science, education and collaboration. #ESMOGI26 #esmomeetings
🔗 buff.ly/HNkIEuN
🔗 buff.ly/HNkIEuN
December 30, 2025 at 8:01 AM
📣 The future of GI oncology is written together. Registration is now open for the ESMO Gastrointestinal Cancers Congress 2026, taking place in Munich, Germany, 1–4 July. A global stage for science, education and collaboration. #ESMOGI26 #esmomeetings
🔗 buff.ly/HNkIEuN
🔗 buff.ly/HNkIEuN
👉 Prof. Michel Ducreux, ESMO GI 2026 Scientific Co-Chair, invites you to be where the future of GI oncology is shaped.
📍 Munich & online | 🗓️ 1–4 July 2026
⏰ Early reg: 15 April
🔗 Register now: https://ow.ly/z9mz50YpvWB
#ESMOGI26 #esmomeetings
📍 Munich & online | 🗓️ 1–4 July 2026
⏰ Early reg: 15 April
🔗 Register now: https://ow.ly/z9mz50YpvWB
#ESMOGI26 #esmomeetings
March 10, 2026 at 2:01 PM
👉 Prof. Michel Ducreux, ESMO GI 2026 Scientific Co-Chair, invites you to be where the future of GI oncology is shaped.
📍 Munich & online | 🗓️ 1–4 July 2026
⏰ Early reg: 15 April
🔗 Register now: https://ow.ly/z9mz50YpvWB
#ESMOGI26 #esmomeetings
📍 Munich & online | 🗓️ 1–4 July 2026
⏰ Early reg: 15 April
🔗 Register now: https://ow.ly/z9mz50YpvWB
#ESMOGI26 #esmomeetings
Michel P Ducreaux pondered the future of #HCC at #ESMOGI26's closing remarks on this sunny Saturday morning in Munich - discussing the future for combinations of systemic and local therapies in #GICancer treatment
July 4, 2026 at 5:03 PM
Michel P Ducreaux pondered the future of #HCC at #ESMOGI26's closing remarks on this sunny Saturday morning in Munich - discussing the future for combinations of systemic and local therapies in #GICancer treatment
👉 Prof. Pierre Laurent‑Puig, ESMO GI 2026 Scientific Committee member, invites all experts in GI cancers to bring their science to the meeting that matters.
📍 Munich & online | 🗓 1–4 July 2026
📝 Submit your abstract now!
https://ow.ly/iKKs50YnSzf
#ESMOGI26 #esmomeetings
📍 Munich & online | 🗓 1–4 July 2026
📝 Submit your abstract now!
https://ow.ly/iKKs50YnSzf
#ESMOGI26 #esmomeetings
March 4, 2026 at 8:30 AM
👉 Prof. Pierre Laurent‑Puig, ESMO GI 2026 Scientific Committee member, invites all experts in GI cancers to bring their science to the meeting that matters.
📍 Munich & online | 🗓 1–4 July 2026
📝 Submit your abstract now!
https://ow.ly/iKKs50YnSzf
#ESMOGI26 #esmomeetings
📍 Munich & online | 🗓 1–4 July 2026
📝 Submit your abstract now!
https://ow.ly/iKKs50YnSzf
#ESMOGI26 #esmomeetings
#ESMOGI26: #mCRC tumours with no ctDNA-identified anti-EGFR resistance genes responded to continued cetuximab in the phase II CAPRI-2 #ClinicalTrial, supporting the use of #LiquidBiopsy to guide rechallenge. #ESMODailyReporter 🔗 https://ow.ly/xEZm50Zjier
July 1, 2026 at 3:25 PM
#ESMOGI26: #mCRC tumours with no ctDNA-identified anti-EGFR resistance genes responded to continued cetuximab in the phase II CAPRI-2 #ClinicalTrial, supporting the use of #LiquidBiopsy to guide rechallenge. #ESMODailyReporter 🔗 https://ow.ly/xEZm50Zjier
👉 Prof. Gerald Prager, ESMO GI 2026 Scientific Committee member, invites you to share work that can spark the next wave of innovation in GI oncology.
📍 Munich & online | 🗓 1–4 July 2026
📝 Submit your abstract by 7 April
🔗 https://ow.ly/Pvpm50YB9jx
#ESMOGI26 #esmomeetings
📍 Munich & online | 🗓 1–4 July 2026
📝 Submit your abstract by 7 April
🔗 https://ow.ly/Pvpm50YB9jx
#ESMOGI26 #esmomeetings
April 3, 2026 at 6:00 AM
👉 Prof. Gerald Prager, ESMO GI 2026 Scientific Committee member, invites you to share work that can spark the next wave of innovation in GI oncology.
📍 Munich & online | 🗓 1–4 July 2026
📝 Submit your abstract by 7 April
🔗 https://ow.ly/Pvpm50YB9jx
#ESMOGI26 #esmomeetings
📍 Munich & online | 🗓 1–4 July 2026
📝 Submit your abstract by 7 April
🔗 https://ow.ly/Pvpm50YB9jx
#ESMOGI26 #esmomeetings
Prof. Florian Lordick, ESMO GI 2026 Scientific Committee member, invites you to Munich — onsite or online — for a key GI oncology meeting of the year.
🗓️ 1–4 July 2026
⏰ Early reg: 15 April
👉 Register now: https://ow.ly/FtGR50YcGIt
#ESMOGI26 #esmomeetings
🗓️ 1–4 July 2026
⏰ Early reg: 15 April
👉 Register now: https://ow.ly/FtGR50YcGIt
#ESMOGI26 #esmomeetings
February 18, 2026 at 3:00 PM
Prof. Florian Lordick, ESMO GI 2026 Scientific Committee member, invites you to Munich — onsite or online — for a key GI oncology meeting of the year.
🗓️ 1–4 July 2026
⏰ Early reg: 15 April
👉 Register now: https://ow.ly/FtGR50YcGIt
#ESMOGI26 #esmomeetings
🗓️ 1–4 July 2026
⏰ Early reg: 15 April
👉 Register now: https://ow.ly/FtGR50YcGIt
#ESMOGI26 #esmomeetings
👉 Join #ESMOGI26 in Munich (1–4 July)—registration is still open!
Discover the latest in GI oncology: immunotherapy advances, precision medicine, ctDNA, AI innovation, and multidisciplinary care across major GI tumour types.
🔗 https://ow.ly/iaE150ZaYuI
#esmomeetings
Discover the latest in GI oncology: immunotherapy advances, precision medicine, ctDNA, AI innovation, and multidisciplinary care across major GI tumour types.
🔗 https://ow.ly/iaE150ZaYuI
#esmomeetings
June 15, 2026 at 12:02 PM
👉 Join #ESMOGI26 in Munich (1–4 July)—registration is still open!
Discover the latest in GI oncology: immunotherapy advances, precision medicine, ctDNA, AI innovation, and multidisciplinary care across major GI tumour types.
🔗 https://ow.ly/iaE150ZaYuI
#esmomeetings
Discover the latest in GI oncology: immunotherapy advances, precision medicine, ctDNA, AI innovation, and multidisciplinary care across major GI tumour types.
🔗 https://ow.ly/iaE150ZaYuI
#esmomeetings
🎯Key takeaways from the EORTC #ASPIRE study presented at #ESMOGI26.
ASPIRE is one of the largest analyses comparing PD-L1 CPS & TAP scoring in gastroesophageal adenocarcinoma (GEA).
Congratulations to Dr Petrillo & all ASPIRE collaborators.
@myesmo.bsky.social #EORTCgastrointestinal
👇
ASPIRE is one of the largest analyses comparing PD-L1 CPS & TAP scoring in gastroesophageal adenocarcinoma (GEA).
Congratulations to Dr Petrillo & all ASPIRE collaborators.
@myesmo.bsky.social #EORTCgastrointestinal
👇
July 6, 2026 at 12:42 PM
🎯Key takeaways from the EORTC #ASPIRE study presented at #ESMOGI26.
ASPIRE is one of the largest analyses comparing PD-L1 CPS & TAP scoring in gastroesophageal adenocarcinoma (GEA).
Congratulations to Dr Petrillo & all ASPIRE collaborators.
@myesmo.bsky.social #EORTCgastrointestinal
👇
ASPIRE is one of the largest analyses comparing PD-L1 CPS & TAP scoring in gastroesophageal adenocarcinoma (GEA).
Congratulations to Dr Petrillo & all ASPIRE collaborators.
@myesmo.bsky.social #EORTCgastrointestinal
👇
Professionals del #VHIO van presentar a #ESMOGI26 nous avenços en tumors gastrointestinals.
La participació va incloure dades de l'assaig de fase III KRYSTAL-10, presentades per Josep Tabernero, sessions educatives amb Elena Élez i diversos pòster.
➡️ https://linke.to/ESMOGI26VHIO_Cat
La participació va incloure dades de l'assaig de fase III KRYSTAL-10, presentades per Josep Tabernero, sessions educatives amb Elena Élez i diversos pòster.
➡️ https://linke.to/ESMOGI26VHIO_Cat
July 9, 2026 at 7:02 PM
Professionals del #VHIO van presentar a #ESMOGI26 nous avenços en tumors gastrointestinals.
La participació va incloure dades de l'assaig de fase III KRYSTAL-10, presentades per Josep Tabernero, sessions educatives amb Elena Élez i diversos pòster.
➡️ https://linke.to/ESMOGI26VHIO_Cat
La participació va incloure dades de l'assaig de fase III KRYSTAL-10, presentades per Josep Tabernero, sessions educatives amb Elena Élez i diversos pòster.
➡️ https://linke.to/ESMOGI26VHIO_Cat
📣 Continue your #ESMOGI26 experience online.
Sessions with speaker permission are now available on demand on #OncologyPRO for registered delegates and ESMO members.
Revisit key insights and stay connected to the latest developments in oncology.
🔗 https://ow.ly/VICO50ZkBs2
#esmomeetings
Sessions with speaker permission are now available on demand on #OncologyPRO for registered delegates and ESMO members.
Revisit key insights and stay connected to the latest developments in oncology.
🔗 https://ow.ly/VICO50ZkBs2
#esmomeetings
July 6, 2026 at 3:00 PM
📣 Continue your #ESMOGI26 experience online.
Sessions with speaker permission are now available on demand on #OncologyPRO for registered delegates and ESMO members.
Revisit key insights and stay connected to the latest developments in oncology.
🔗 https://ow.ly/VICO50ZkBs2
#esmomeetings
Sessions with speaker permission are now available on demand on #OncologyPRO for registered delegates and ESMO members.
Revisit key insights and stay connected to the latest developments in oncology.
🔗 https://ow.ly/VICO50ZkBs2
#esmomeetings
#ESMOGI26 - Fanregratinib montre un signal robuste en phase II dans le CCI lié à FGFR2 ipharmacenter.com/post/esmo-ga... #pharma #Oncologie #Oncotwitter #OncoAlert #Cancer #innovation #HUTCHMed #actualités #dernièreminute #news #breakingnews
ESMO Gastrointestinal Cancers Congress 2026 | iPharmaCenter
Fanregratinib Delivers Strong Phase II Signal in FGFR2‑Driven iCCAHUTCHMED tested its FGFR inhibitor fanregratinib (HMPL‑453) in a registration‑oriented Phase II study run at 53 hospitals across China...
ipharmacenter.com
June 29, 2026 at 10:57 AM
#ESMOGI26 - Fanregratinib montre un signal robuste en phase II dans le CCI lié à FGFR2 ipharmacenter.com/post/esmo-ga... #pharma #Oncologie #Oncotwitter #OncoAlert #Cancer #innovation #HUTCHMed #actualités #dernièreminute #news #breakingnews
#Enhertu Gains EU Tumour‑Agnostic Approval For HER2‑Positive Metastatic Solid Tumours
www.ipharmacenter.com/post/enhertu...
#news #pharma #EMAApproval #media #breaking #cancer #oncology #OncoTwitter #ESMOGI26
www.ipharmacenter.com/post/enhertu...
#news #pharma #EMAApproval #media #breaking #cancer #oncology #OncoTwitter #ESMOGI26
Enhertu Gains EU Tumour‑Agnostic Approval For HER2‑Positive Metastatic Solid Tumours | iPharmaCenter
The European Commission (EC) has granted tumor-agnostic approval for Enhertu (trastuzumab deruxtecan) to treat adult patients presenting with unresectable or metastatic HER2-positive solid tumors. Bec...
www.ipharmacenter.com
June 29, 2026 at 5:03 PM
#Enhertu Gains EU Tumour‑Agnostic Approval For HER2‑Positive Metastatic Solid Tumours
www.ipharmacenter.com/post/enhertu...
#news #pharma #EMAApproval #media #breaking #cancer #oncology #OncoTwitter #ESMOGI26
www.ipharmacenter.com/post/enhertu...
#news #pharma #EMAApproval #media #breaking #cancer #oncology #OncoTwitter #ESMOGI26
A 🩸 blood test for #ctDNA may help identify which patients with #colorectalcancer that has spread to the liver are most likely to benefit from #chemotherapy after #surgery, according to new research from 🇯🇵 Hyogo Medical University, presented at @myesmo.bsky.social's #ESMOGI26.
Colorectal cancer: blood test shows who benefits from chemotherapy after surgery
Study also suggests that method could potentially spare other patients unnecessary treatment
healthcare-in-europe.com
July 10, 2026 at 10:34 AM
A 🩸 blood test for #ctDNA may help identify which patients with #colorectalcancer that has spread to the liver are most likely to benefit from #chemotherapy after #surgery, according to new research from 🇯🇵 Hyogo Medical University, presented at @myesmo.bsky.social's #ESMOGI26.
Enhertu obtient une approbation agnostique des tumeurs dans l'UE pour les tumeurs solides métastatiques HER2-positives www.ipharmacenter.com/post/enhertu...
#actualités #pharma #AutorisationEMA #médias #flashinfo #cancer #oncologie #OncoTwitter #ESMOGI26
#actualités #pharma #AutorisationEMA #médias #flashinfo #cancer #oncologie #OncoTwitter #ESMOGI26
Enhertu Gains EU Tumour‑Agnostic Approval For HER2‑Positive Metastatic Solid Tumours | iPharmaCenter
The European Commission (EC) has granted tumor-agnostic approval for Enhertu (trastuzumab deruxtecan) to treat adult patients presenting with unresectable or metastatic HER2-positive solid tumors. Bec...
www.ipharmacenter.com
June 29, 2026 at 5:05 PM
Enhertu obtient une approbation agnostique des tumeurs dans l'UE pour les tumeurs solides métastatiques HER2-positives www.ipharmacenter.com/post/enhertu...
#actualités #pharma #AutorisationEMA #médias #flashinfo #cancer #oncologie #OncoTwitter #ESMOGI26
#actualités #pharma #AutorisationEMA #médias #flashinfo #cancer #oncologie #OncoTwitter #ESMOGI26
At #ESMOGI26, Dr Kozo Kataoka discusses GALAXY data showing postoperative ctDNA can identify colorectal liver metastasis patients most likely to benefit from adjuvant chemotherapy. Watch the interview👉 https://bit.ly/4xxdpmA
#CRC #ctDNA #MRD #PrecisionMedicine
#CRC #ctDNA #MRD #PrecisionMedicine
ctDNA MRD status predicts survival and adjuvant chemo benefit in resected colorectal liver metastas - ecancer
Dr Kozo Kataoka speaks to ecancer about the ctDNA status and adjuvant chemotherapy after resection of colorectal liver metastases. The study found that the role
bit.ly
August 26, 2026 at 8:47 AM
At #ESMOGI26, Dr Kozo Kataoka discusses GALAXY data showing postoperative ctDNA can identify colorectal liver metastasis patients most likely to benefit from adjuvant chemotherapy. Watch the interview👉 https://bit.ly/4xxdpmA
#CRC #ctDNA #MRD #PrecisionMedicine
#CRC #ctDNA #MRD #PrecisionMedicine
At #ESMOGI26, DrPark Memorial Sloan Kettering Cancer Center discusses GLEAM results. Zolbetuximab + gemcitabine and nab-paclitaxel did not improve survival in CLDN18.2-positive MPC, highlighting the need for better patient selection and combination strategies. Watch the video👉https://bit.ly/3UyJiN6
Zolbetuximab plus chemo in CLDN18.2-positive metastatic pancreatic cancer does not improve OS - ecancer
Dr Wungki Park speaks to ecancer about the phase II GLEAM study, which evaluated zolbetuximab plus gemcitabine and nab-paclitaxel in patients with claudin 18 is
bit.ly
August 25, 2026 at 1:59 PM
At #ESMOGI26, DrPark Memorial Sloan Kettering Cancer Center discusses GLEAM results. Zolbetuximab + gemcitabine and nab-paclitaxel did not improve survival in CLDN18.2-positive MPC, highlighting the need for better patient selection and combination strategies. Watch the video👉https://bit.ly/3UyJiN6
At #ESMOGI26, Josep Tabernero discusses that adagrasib plus cetuximab achieved higher response rates, including more CRs, in previously treated KRAS G12C-mutated mCRC, but did not significantly improve PFS or OS vs chemotherapy. Watch the interview👉https://bit.ly/4qxthTJ
Adagrasib plus cetuximab shows activity but does not improve survival in KRAS G12C-mutated metastatic colorectal cancer - ecancer
Dr Josep Tabernero speaks to ecancer about the final analysis of the phase III KRYSTAL-10 trial evaluating adagrasib plus cetuximab as second-line treatment for
bit.ly
August 24, 2026 at 4:01 PM
At #ESMOGI26, Josep Tabernero discusses that adagrasib plus cetuximab achieved higher response rates, including more CRs, in previously treated KRAS G12C-mutated mCRC, but did not significantly improve PFS or OS vs chemotherapy. Watch the interview👉https://bit.ly/4qxthTJ
At #ESMOGI26, Dr Michele Milella discusses targeted intratumoural phosphorus-32 microparticles plus FOLFIRINOX in uLAPC, showing encouraging local disease control and supporting further study of this combined approach. Watch the interview👉https://bit.ly/4gPfULa
P-32 microparticle brachytherapy plus FOLFIRINOX shows promising local control in unresectable pancreatic cancer - ecancer
Dr Michele Milella speaks to ecancer about an open-label, multi-centre, randomised study of TaRgeted intratumoural placement of phosphorous-32 microparticles ad
bit.ly
August 24, 2026 at 8:59 AM
At #ESMOGI26, Dr Michele Milella discusses targeted intratumoural phosphorus-32 microparticles plus FOLFIRINOX in uLAPC, showing encouraging local disease control and supporting further study of this combined approach. Watch the interview👉https://bit.ly/4gPfULa